LSCH��icL�i �N � �� ���iN " /product-tag/adipotideftpp/feed/2b5_WC_T.2230,2b5_tax,2b5_URL.1bfb9c341fdbf9e33d758060ddf80fb0,2b5_T.2230,2b5_X-Powered-By: PHP/8.4.19
Last-Modified: Fri, 13 Feb 2026 05:33:38 GMT
ETag: "0ae67c2da9112ca347f6d1405fbeb50e"
Link: <https://sumiagro.org/wp-json/>; rel="https://api.w.org/"
Link: <https://sumiagro.org/wp-json/wp/v2/product_tag/2230>; rel="alternate"; title="JSON"; type="application/json"
Content-Type: application/rss+xml; charset=UTF-8
X-LiteSpeed-Cache-Control: public,max-age=604800
X-LiteSpeed-Tag: 2b5_WC_T.2230,2b5_tax,2b5_URL.1bfb9c341fdbf9e33d758060ddf80fb0,2b5_T.2230,2b5_
<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
xmlns:content="http://purl.org/rss/1.0/modules/content/"
xmlns:wfw="http://wellformedweb.org/CommentAPI/"
xmlns:dc="http://purl.org/dc/elements/1.1/"
xmlns:atom="http://www.w3.org/2005/Atom"
xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
>
<channel>
<title>Adipotide(FTPP) – SUMI AGRO</title>
<atom:link href="https://sumiagro.org/product-tag/adipotideftpp/feed/" rel="self" type="application/rss+xml" />
<link>https://sumiagro.org</link>
<description>Customer is Gold!</description>
<lastBuildDate>Fri, 13 Feb 2026 05:33:38 +0000</lastBuildDate>
<language>en-US</language>
<sy:updatePeriod>
hourly </sy:updatePeriod>
<sy:updateFrequency>
1 </sy:updateFrequency>
<generator>https://wordpress.org/?v=6.9.4</generator>
<image>
<url>https://sumiagro.org/wp-content/uploads/2026/01/cropped-logo-300x82-1-32x32.png</url>
<title>Adipotide(FTPP) – SUMI AGRO</title>
<link>https://sumiagro.org</link>
<width>32</width>
<height>32</height>
</image>
<item>
<title>DSIP ( DS5, DS10)</title>
<link>https://sumiagro.org/product/dsip-ds5-ds10/</link>
<comments>https://sumiagro.org/product/dsip-ds5-ds10/#respond</comments>
<dc:creator><![CDATA[Administrator]]></dc:creator>
<pubDate>Fri, 13 Feb 2026 05:33:37 +0000</pubDate>
<guid isPermaLink="false">https://sumiagro.org/?post_type=product&p=29501</guid>
<description><![CDATA[Delta Sleep-Inducing Peptide (DSIP) is a neuropeptide that induces delta sleep in mammals. Studies have shown that DSIP plasma concentrations and the human circadian rhythm are correlated and that DSIP concentrations are dependent on the initiation of sleep. Interestingly DSIP has the ability to cross the blood-brain barrier and can be absorbed from the gut. This neuropeptide is found in plasma, peripheral organs and neurons and its functions extend beyond inducing sleep. For example it has the ability to affect levels of hormones, neurotransmitters and psychological performance. It has also been found that schizophrenia and depression patients have lower concentrations of DSIP in their cerebrospinal fluid and plasma. Clinically DFSIP has already been used to treat opioid and alcohol withdrawal in reducing symptoms felt by patients.
 
<div class="row">
<div class="col-12 col-md-3">CAS No</div>
<div class="col-12 col-md-9">[62568-57-4]</div>
</div>
<div class="row">
<div class="col-12 col-md-3">Synonyms</div>
<div class="col-12 col-md-9">Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu</div>
</div>
<div class="row">
<div class="col-12 col-md-3">Product Code</div>
<div class="col-12 col-md-9">PDS-4054</div>
</div>
<div class="row">
<div class="col-12 col-md-3">Chemical Formula</div>
<div class="col-12 col-md-9">C<sub>35</sub>H<sub>48</sub>N<sub>10</sub>O<sub>15</sub></div>
</div>
<div class="row">
<div class="col-12 col-md-3">Molecular Weight</div>
<div class="col-12 col-md-9">848.82 g/mol</div>
</div>
<div class="row">
<div class="col-12 col-md-3">Smiles</div>
<div class="col-12 col-md-9">C[C@@H](C(=O)NCC(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N</div>
</div>
<div class="row">
<div class="col-12 col-md-3">Long Term Storage</div>
<div class="col-12 col-md-9">store at <-15°C, close container well</div>
</div>
 
 
 ]]></description>
<content:encoded><![CDATA[<p>Delta Sleep-Inducing Peptide (DSIP) is a neuropeptide that induces delta sleep in mammals. Studies have shown that DSIP plasma concentrations and the human circadian rhythm are correlated and that DSIP concentrations are dependent on the initiation of sleep. Interestingly DSIP has the ability to cross the blood-brain barrier and can be absorbed from the gut. This neuropeptide is found in plasma, peripheral organs and neurons and its functions extend beyond inducing sleep. For example it has the ability to affect levels of hormones, neurotransmitters and psychological performance. It has also been found that schizophrenia and depression patients have lower concentrations of DSIP in their cerebrospinal fluid and plasma. Clinically DFSIP has already been used to treat opioid and alcohol withdrawal in reducing symptoms felt by patients.</p>
]]></content:encoded>
<wfw:commentRss>https://sumiagro.org/product/dsip-ds5-ds10/feed/</wfw:commentRss>
<slash:comments>0</slash:comments>
</item>
<item>
<title>BPC157 ( BC5, BC10 )</title>
<link>https://sumiagro.org/product/bpc157-bc5-bc10/</link>
<comments>https://sumiagro.org/product/bpc157-bc5-bc10/#respond</comments>
<dc:creator><![CDATA[Administrator]]></dc:creator>
<pubDate>Fri, 13 Feb 2026 05:25:57 +0000</pubDate>
<guid isPermaLink="false">https://sumiagro.org/?post_type=product&p=29499</guid>
<description><![CDATA[BPC 157 (Body Protection Compound 157) is a synthetic peptide derived from a protein found in the human stomach. It’s also known as Pentadecapeptide, PLD-116, PL-10, PL14736 and Bepecin.
 
<div class="elementor-element elementor-element-c6add63 elementor-widget elementor-widget-text-editor" data-id="c6add63" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
<div class="elementor-widget-container"><span class="tech-field-titles">Molecular Weight: </span>1419.54</div>
</div>
<div class="elementor-element elementor-element-f886383 elementor-widget elementor-widget-text-editor" data-id="f886383" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
<div class="elementor-widget-container"><span class="tech-field-titles">Purity: </span>≥95%</div>
</div>
<div class="elementor-element elementor-element-b197dfa elementor-widget elementor-widget-text-editor" data-id="b197dfa" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
<div class="elementor-widget-container"><span class="tech-field-titles">Validation: </span>Exhibits correct molecular weight</div>
</div>
<div class="elementor-element elementor-element-7bbeab1 elementor-widget elementor-widget-text-editor" data-id="7bbeab1" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
<div class="elementor-widget-container"><span class="tech-field-titles">Storage: </span>Store peptide in DRY form at 0-5°C.</div>
</div>
<div class="elementor-element elementor-element-a8f731a elementor-widget elementor-widget-heading" data-id="a8f731a" data-element_type="widget" data-e-type="widget" data-widget_type="heading.default">
<div class="elementor-widget-container">
<p class="elementor-heading-title elementor-size-default"><span class="tech-field-titles">Appearance: </span>White powder</p>
</div>
</div>
<div class="elementor-element elementor-element-c6e0f3f elementor-widget elementor-widget-text-editor" data-id="c6e0f3f" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
<div class="elementor-widget-container"><span class="tech-field-titles">Contents: </span>Each vial contains 1 mg NET peptide.</div>
</div>]]></description>
<content:encoded><![CDATA[<p>BPC 157 is a peptide derived from a protein found in the human stomach. It is lauded for its potential healing properties, particularly for ligaments, tendons, and joints. In animal studies, BPC 157 has shown promise in:</p>
<ul data-spread="false">
<li>Accelerating wound healing.</li>
<li>Reducing inflammation.</li>
<li>Enhancing tendon and ligament repair.</li>
</ul>
]]></content:encoded>
<wfw:commentRss>https://sumiagro.org/product/bpc157-bc5-bc10/feed/</wfw:commentRss>
<slash:comments>0</slash:comments>
</item>
<item>
<title>AICAR (AR50)</title>
<link>https://sumiagro.org/product/aicar-ar50/</link>
<comments>https://sumiagro.org/product/aicar-ar50/#respond</comments>
<dc:creator><![CDATA[Administrator]]></dc:creator>
<pubDate>Fri, 13 Feb 2026 05:15:18 +0000</pubDate>
<guid isPermaLink="false">https://sumiagro.org/?post_type=product&p=29497</guid>
<description><![CDATA[<div class="grid grid-cols-1 md:grid-cols-3 lg:gap-2">
<h6 id="cas-number" class="text-sm mt-0 mb-1 font-normal font-sans tracking-wide text-[#65797C] w-52">CAS number</h6>
2627-69-2
</div>
<div class="grid grid-cols-1 md:grid-cols-3 lg:gap-2">
<h6 id="purity" class="text-sm mt-0 mb-1 font-normal font-sans tracking-wide text-[#65797C] w-52">Purity</h6>
>98%
</div>
<div class="grid grid-cols-1 md:grid-cols-3 lg:gap-2">
<h6 id="form" class="text-sm mt-0 mb-1 font-normal font-sans tracking-wide text-[#65797C] w-52">Form</h6>
Solid
<p class="lg:col-span-2 font-normal text-base text-[#000000] leading-6 !mt-0 break-words"><a class="text-[#378089] cursor-pointer underline" data-di-id="di-id-518cf6b1-ac2b679c">See storage information</a></p>
</div>
<div class="grid grid-cols-1 md:grid-cols-3 lg:gap-2">
<h6 id="molecular-weight" class="text-sm mt-0 mb-1 font-normal font-sans tracking-wide text-[#65797C] w-52">Molecular weight</h6>
258.23 Da
</div>
<div class="grid grid-cols-1 md:grid-cols-3 lg:gap-2">
<h6 id="molecular-formula" class="text-sm mt-0 mb-1 font-normal font-sans tracking-wide text-[#65797C] w-52">Molecular formula</h6>
C<sub>9</sub>H<sub>1</sub><sub>4</sub>N<sub>4</sub>O<sub>5</sub>
</div>
<div class="grid grid-cols-1 md:grid-cols-3 lg:gap-2">
<h6 id="pubchem" class="text-sm mt-0 mb-1 font-normal font-sans tracking-wide text-[#65797C] w-52">PubChem</h6>
17513
</div>
<div class="grid grid-cols-1 md:grid-cols-3 lg:gap-2">
<h6 id="nature" class="text-sm mt-0 mb-1 font-normal font-sans tracking-wide text-[#65797C] w-52">Nature</h6>
Synthetic
</div>
<div class="grid grid-cols-1 md:grid-cols-3 lg:gap-2">
<h6 id="biochemical-name" class="text-sm mt-0 mb-1 font-normal font-sans tracking-wide text-[#65797C] w-52">Biochemical name</h6>
Acadesine
</div>
<div class="grid grid-cols-1 md:grid-cols-3 lg:gap-2">
<h6 id="biological-description" class="text-sm mt-0 mb-1 font-normal font-sans tracking-wide text-[#65797C] w-52">Biological description</h6>
Cell-permeable activator of AMP-activated protein kinase. Is taken up into cells by adenosine transporters and phosphorylated by adenosine kinase to the active nucleotide ZMP (5-aminoimidazole-4-carboxamide ribonucleoside), which mimics effects of AMP on the AMPK system. Active in vivo and in vitro.
</div>
<div class="grid grid-cols-1 md:grid-cols-3 lg:gap-2">
<h6 id="canonical-smiles" class="text-sm mt-0 mb-1 font-normal font-sans tracking-wide text-[#65797C] w-52">Canonical smiles</h6>
C1=NC(=C(N1C2C(C(C(O2)CO)O)O)N)C(=O)N
</div>
<div class="grid grid-cols-1 md:grid-cols-3 lg:gap-2">
<h6 id="isomeric-smiles" class="text-sm mt-0 mb-1 font-normal font-sans tracking-wide text-[#65797C] w-52">Isomeric smiles</h6>
C1=NC(=C(N1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)N)C(=O)N
</div>
<div class="grid grid-cols-1 md:grid-cols-3 lg:gap-2">
<h6 id="iupac-name" class="text-sm mt-0 mb-1 font-normal font-sans tracking-wide text-[#65797C] w-52">IUPAC Name</h6>
5-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]imidazole-4-carboxamide
</div>]]></description>
<content:encoded><![CDATA[<p>Potent AMPK activator. AICAR activates AMPK due to increased phosphorylation, causes phosphorylation and inactivation of HMG-CoA reductase, and almost total cessation of fatty acid and sterol synthesis. AICAR causes ZMP (a cellular mimetic of AMP) to accumulate inside the cell but does not perturb the cellular contents of ATP, ADP or AMP, and induces differentiation of acute myeloid leukemia cells, and astroglial differentiation of neural stem cells via activating the JAK/STAT3 pathway independently of AMP-activated protein kinase. AICAR can also significantly up-regulate pluripotency-associated genes and down-regulate differentiation-associated transcription factors.</p>
]]></content:encoded>
<wfw:commentRss>https://sumiagro.org/product/aicar-ar50/feed/</wfw:commentRss>
<slash:comments>0</slash:comments>
</item>
<item>
<title>MAZDUTIDE ( MDT5 MDT10 )</title>
<link>https://sumiagro.org/product/mazdutide-mdt5-mdt10/</link>
<comments>https://sumiagro.org/product/mazdutide-mdt5-mdt10/#respond</comments>
<dc:creator><![CDATA[Administrator]]></dc:creator>
<pubDate>Fri, 13 Feb 2026 05:01:42 +0000</pubDate>
<guid isPermaLink="false">https://sumiagro.org/?post_type=product&p=29494</guid>
<description><![CDATA[<div class="padded nooverflow">Chemical. CAS: 2259884-03-0. Formula: C210H322N46O67. MW: 4563.1. Soluble in water or DMSO (both 1mg/ml). Mazdutide is a novel long-acting dual glucagon-like peptide-1 (GLP-1) receptor and glucagon receptor (GCGR) agonist. Mazdutide potently activates the GLP-1R signaling pathway to stimulate glucose-dependent insulin secretion through activity at the GCG receptor (GCGR) or the GLP-1R. Mazdutide is a synthetic peptide analog of the gut peptide hormone oxyntomodulin that reduces body weight in both Gcgr-/- and Glp1r-/- mice. Mazdutide binds human and mouse GCGR (Ki: 17.7nM and 15.9nM, respectively) and GLP-1R (Ki: 28.6nM and 25.1nM, respectively) and stimulates insulin secretion from mouse islets (EC50: 5.2 nM). Mazdutide is used in studies of obesity and type 2 diabetes (T2D) and is designed enhancing energy expenditure and fat metabolism. Mazdutide comprises a 33 amino acid linear synthetic peptide conjugated to a C20 fatty diacid moiety through a hydrophilic linker at the lysine residue at position 20. Due to this moiety, the compound is highly bound to albumin in the plasma which prolongs its half-life. It contains one non-coded amino acid residue (Aib, alpha-amino isobutyric acid) at position 2.</div>
<div class="separator"></div>
<div class="column-20 floatleft">
<div class="padded"><strong>Molecular Formula:</strong></div>
</div>
<div class="padded nooverflow">C210H322N46O67</div>
<div class="separator"></div>
<div class="column-20 floatleft">
<div class="padded"><strong>Molecular Weight:</strong></div>
</div>
<div class="padded nooverflow">4563.1</div>
<div class="separator"></div>
<div class="column-20 floatleft">
<div class="padded"><strong>Package Type:</strong></div>
</div>
<div class="padded nooverflow">Vial</div>
<div class="separator"></div>
<div class="column-20 floatleft">
<div class="padded"><strong>Product Description:</strong></div>
</div>
<div class="padded nooverflow">Mazdutide is a novel long-acting dual glucagon-like peptide-1 (GLP-1) receptor and glucagon receptor (GCGR) agonist. Mazdutide potently activates the GLP-1R signaling pathway to stimulate glucose-dependent insulin secretion through activity at the GCG receptor (GCGR) or the GLP-1R. Mazdutide is a synthetic peptide analog of the gut peptide hormone oxyntomodulin that reduces body weight in both Gcgr-/- and Glp1r-/- mice. Mazdutide binds human and mouse GCGR (Ki: 17.7nM and 15.9nM, respectively) and GLP-1R (Ki: 28.6nM and 25.1nM, respectively) and stimulates insulin secretion from mouse islets (EC50: 5.2 nM). Mazdutide is used in studies of obesity and type 2 diabetes (T2D) and is designed enhancing energy expenditure and fat metabolism. Mazdutide comprises a 33 amino acid linear synthetic peptide conjugated to a C20 fatty diacid moiety through a hydrophilic linker at the lysine residue at position 20. Due to this moiety, the compound is highly bound to albumin in the plasma which prolongs its half-life. It contains one non-coded amino acid residue (Aib, alpha-amino isobutyric acid) at position 2.</div>
<div class="separator"></div>
<div class="column-20 floatleft">
<div class="padded"><strong>Purity:</strong></div>
</div>
<div class="padded nooverflow">>98% (HPLC)</div>
<div class="separator"></div>
<div class="column-20 floatleft">
<div class="padded"><strong>Sequence:</strong></div>
</div>
<div class="padded nooverflow">H-His-{Aib}-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Glu-Lys-Lys-Ala-{diacid-C20-gamma-Glu-(AEEA)2-Lys}-Glu-Phe-Val-Glu-Trp-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-NH2</div>]]></description>
<content:encoded><![CDATA[<p>Mazdutide is a novel long-acting dual glucagon-like peptide-1 (GLP-1) receptor and glucagon receptor (GCGR) agonist. Mazdutide potently activates the GLP-1R signaling pathway to stimulate glucose-dependent insulin secretion through activity at the GCG receptor (GCGR) or the GLP-1R. Mazdutide is a synthetic peptide analog of the gut peptide hormone oxyntomodulin that reduces body weight in both Gcgr-/- and Glp1r-/- mice. Mazdutide binds human and mouse GCGR (Ki: 17.7nM and 15.9nM, respectively) and GLP-1R (Ki: 28.6nM and 25.1nM, respectively) and stimulates insulin secretion from mouse islets (EC50: 5.2 nM). Mazdutide is used in studies of obesity and type 2 diabetes (T2D) and is designed enhancing energy expenditure and fat metabolism. Mazdutide comprises a 33 amino acid linear synthetic peptide conjugated to a C20 fatty diacid moiety through a hydrophilic linker at the lysine residue at position 20. Due to this moiety, the compound is highly bound to albumin in the plasma which prolongs its half-life. It contains one non-coded amino acid residue (Aib, alpha-amino isobutyric acid) at position 2.</p>
]]></content:encoded>
<wfw:commentRss>https://sumiagro.org/product/mazdutide-mdt5-mdt10/feed/</wfw:commentRss>
<slash:comments>0</slash:comments>
</item>
<item>
<title>ADIPOTIDE(FTPP) (AP2,AP5,AP10,AP25,AP50)</title>
<link>https://sumiagro.org/product/adipotideftpp-ap2ap5ap10ap25ap50/</link>
<comments>https://sumiagro.org/product/adipotideftpp-ap2ap5ap10ap25ap50/#respond</comments>
<dc:creator><![CDATA[Administrator]]></dc:creator>
<pubDate>Fri, 13 Feb 2026 04:52:14 +0000</pubDate>
<guid isPermaLink="false">https://sumiagro.org/?post_type=product&p=29492</guid>
<description><![CDATA[Adipotide, also known as FTPP or the proapoptotic peptide, is a promising new drug for weight loss and diabetes. It works by targeting and destroying fat cells, leaving the rest of the body unharmed. Studies on primates have shown that adipotide can cause significant weight loss, improve insulin sensitivity, and reduce some of the adverse effects of type 2 diabetes.
<p class="content-heading-para">Adipotide is a research peptide designed to target fat tissue by acting on blood vessels that supply adipose tissue. The dosing guidance below reflects a <strong>weight-based protocol</strong> commonly expressed as <strong>mcg per lb per dose</strong>.</p>
<p class="content-heading-para"><strong>Dosing (Weight-Based):</strong>
<em>Reference formula:</em> <strong>4.53 mcg per lb</strong> (per dose).
<em>Frequency:</em> Commonly listed as <strong>once daily</strong>.</p>
<table class="professional-table">
<tbody>
<tr>
<td>100–150</td>
<td>455–680 mcg</td>
<td>4.53 mcg/lb</td>
</tr>
<tr>
<td>151–200</td>
<td>685–905 mcg</td>
<td>4.53 mcg/lb</td>
</tr>
<tr>
<td>201–250</td>
<td>910–1150 mcg</td>
<td>4.53 mcg/lb</td>
</tr>
</tbody>
</table>
 ]]></description>
<content:encoded><![CDATA[<p><strong>Adipotide</strong>, also known as FTPP (CKGGRAKDC-GG-D(KLAKLAK)₂), is a synthetic research peptide designed as a targeted proapoptotic compound that binds to prohibitin receptors on adipose tissue vasculature. Upon receptor engagement, it induces mitochondrial membrane disruption and apoptosis in vascular endothelial cells. Adipotide is utilized in preclinical studies investigating angiogenesis inhibition, vascular remodeling, and adipose tissue metabolism through receptor-mediated peptide targeting.</p>
]]></content:encoded>
<wfw:commentRss>https://sumiagro.org/product/adipotideftpp-ap2ap5ap10ap25ap50/feed/</wfw:commentRss>
<slash:comments>0</slash:comments>
</item>
<item>
<title>CAGRILINTIDE CS5 (CS5 CS10)</title>
<link>https://sumiagro.org/product/cagrilintide-cs5-cs5-cs10/</link>
<comments>https://sumiagro.org/product/cagrilintide-cs5-cs5-cs10/#respond</comments>
<dc:creator><![CDATA[Administrator]]></dc:creator>
<pubDate>Fri, 13 Feb 2026 04:23:22 +0000</pubDate>
<guid isPermaLink="false">https://sumiagro.org/?post_type=product&p=29488</guid>
<description><![CDATA[<div class="padded nooverflow">Chemical. CAS: 1415456-99-3 (free acid). Formula: C194H312N54O59S2 . C2H4O2. MW: 4409.0 . 60.0. Soluble in water (50mg/ml). Cagrilintide is a novel long-acting nonselective amylin receptors (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist. Cagrilintide is a stable synthetic peptide acylated amylin analog. Natural amylin is a pancreatic hormone that induces satiety. Cagrilintide binds human, mouse and rat amylin receptors and is used in studies of obesity and type 2 diabetes (T2D) and is designed enhancing energy expenditure and fat metabolism and decreasing food intake. Cagrilintide is now being developed in combination with the GLP-1 agonist semaglutide as "CagriSema" to achieve sustained weight loss in persons with overweight and obesity. Amylin, released with insulin from beta cells in the pancreas, induces its satiating effect via both the homoeostatic and hedonic regions of the brain. Semaglutide, a GLP-1 receptor agonist, reduces appetite via GLP-1 receptors in the hypothalamus and increases the production of insulin, and reduces glucagon secretion, delaying gastric emptying. These separate, but related mechanisms of action of an amylin-analog and a GLP-1 receptor agonist appear to have an additive effect on appetite reduction. Cagrilintide comprises a 37 amino acid linear synthetic peptide conjugated to a C20 fatty diacid through a hydrophilic linker at the lysine residue at position 1. Due to this moiety, the compound is highly bound to albumin in the plasma which prolongs its half-life. The N-terminus of the amylin peptide is predicted to form a loop, stabilized by a disulfide bond, that points out of the TM area, thereby tolerating N-terminal lipidation.</div>
<div class="separator"></div>
<div class="column-20 floatleft">
<div class="padded"><strong>Molecular Formula:</strong></div>
</div>
<div class="padded nooverflow">C194H312N54O59S2 . C2H4O2</div>
<div class="separator"></div>
<div class="column-20 floatleft">
<div class="padded"><strong>Molecular Weight:</strong></div>
</div>
<div class="padded nooverflow">4409.0 . 60.0</div>
<div class="separator"></div>
<div class="column-20 floatleft">
<div class="padded"><strong>Package Type:</strong></div>
</div>
<div class="padded nooverflow">Vial</div>
<div class="separator"></div>
<div class="column-20 floatleft">
<div class="padded"><strong>Product Description:</strong></div>
</div>
<div class="padded nooverflow">Cagrilintide is a novel long-acting nonselective amylin receptors (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist. Cagrilintide is a stable synthetic peptide acylated amylin analog. Natural amylin is a pancreatic hormone that induces satiety. Cagrilintide binds human, mouse and rat amylin receptors and is used in studies of obesity and type 2 diabetes (T2D) and is designed enhancing energy expenditure and fat metabolism and decreasing food intake. Cagrilintide is now being developed in combination with the GLP-1 agonist semaglutide as "CagriSema" to achieve sustained weight loss in persons with overweight and obesity. Amylin, released with insulin from beta cells in the pancreas, induces its satiating effect via both the homoeostatic and hedonic regions of the brain. Semaglutide, a GLP-1 receptor agonist, reduces appetite via GLP-1 receptors in the hypothalamus and increases the production of insulin, and reduces glucagon secretion, delaying gastric emptying. These separate, but related mechanisms of action of an amylin-analog and a GLP-1 receptor agonist appear to have an additive effect on appetite reduction. Cagrilintide comprises a 37 amino acid linear synthetic peptide conjugated to a C20 fatty diacid through a hydrophilic linker at the lysine residue at position 1. Due to this moiety, the compound is highly bound to albumin in the plasma which prolongs its half-life. The N-terminus of the amylin peptide is predicted to form a loop, stabilized by a disulfide bond, that points out of the TM area, thereby tolerating N-terminal lipidation.</div>
<div class="separator"></div>
<div class="column-20 floatleft">
<div class="padded"><strong>Purity:</strong></div>
</div>
<div class="padded nooverflow">>98% (HPLC)</div>
<div class="separator"></div>
<div class="column-20 floatleft">
<div class="padded"><strong>Sequence:</strong></div>
</div>
<div class="padded nooverflow">{Eicosanedioic acid-gamma-Glu}-Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Glu-Phe-Leu-Arg-His-Ser-Ser-Asn-Asn-Phe-Gly-Pro-Ile-Leu-Pro-Pro-Thr-Asn-Val-Gly-Ser-Asn-Thr-Pro-NH2 (Disulfide bridge:Cys2-Cys7)</div>]]></description>
<content:encoded><![CDATA[<p>Cagrilintide is a novel long-acting nonselective amylin receptors (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist. Cagrilintide is a stable synthetic peptide acylated amylin analog. Natural amylin is a pancreatic hormone that induces satiety. Cagrilintide binds human, mouse and rat amylin receptors and is used in studies of obesity and type 2 diabetes (T2D) and is designed enhancing energy expenditure and fat metabolism and decreasing food intake. Cagrilintide is now being developed in combination with the GLP-1 agonist semaglutide as “CagriSema” to achieve sustained weight loss in persons with overweight and obesity. Amylin, released with insulin from beta cells in the pancreas, induces its satiating effect via both the homoeostatic and hedonic regions of the brain. Semaglutide, a GLP-1 receptor agonist, reduces appetite via GLP-1 receptors in the hypothalamus and increases the production of insulin, and reduces glucagon secretion, delaying gastric emptying. These separate, but related mechanisms of action of an amylin-analog and a GLP-1 receptor agonist appear to have an additive effect on appetite reduction. Cagrilintide comprises a 37 amino acid linear synthetic peptide conjugated to a C20 fatty diacid through a hydrophilic linker at the lysine residue at position 1. Due to this moiety, the compound is highly bound to albumin in the plasma which prolongs its half-life. The N-terminus of the amylin peptide is predicted to form a loop, stabilized by a disulfide bond, that points out of the TM area, thereby tolerating N-terminal lipidation.</p>
]]></content:encoded>
<wfw:commentRss>https://sumiagro.org/product/cagrilintide-cs5-cs5-cs10/feed/</wfw:commentRss>
<slash:comments>0</slash:comments>
</item>
<item>
<title>CIBINETIDE / ARA 290 (RA10)</title>
<link>https://sumiagro.org/product/cibinetide-ara-290-ra10/</link>
<comments>https://sumiagro.org/product/cibinetide-ara-290-ra10/#respond</comments>
<dc:creator><![CDATA[Administrator]]></dc:creator>
<pubDate>Fri, 13 Feb 2026 04:06:28 +0000</pubDate>
<guid isPermaLink="false">https://sumiagro.org/?post_type=product&p=29481</guid>
<description><![CDATA[Diabetic retinopathy a very most common cause of sight loss in people of working age. Sight loss occurs in diabetes because of diabetic macular oedema (DMO) and/or proliferative diabetic retinopathy (PDR), both are complications of diabetes in the eye.
In DMO fluid accumulates in the macula, the area responsible for our central sight. As the fluid accumulates the sight drops. The current treatments for DMO include laser and anti VEGF drugs and steroids. Anti VEGF drugs have been very helpful in the treatment of DMO. However, anti VEGF drugs need to be given by an injection into the eye, an Ophthalmologist (eye specialist) or a specialist nurse (a nurse trained for this purpose) will need to deliver this treatment to patients with DMO in the hospital.
Furthermore, patients require injections every four weeks during the first months of treatment and long term treatment is required. Moreover, not all patients respond to anti VEGFs: In 40% of patients the sight may not improve despite these injections. Because many patients with DMO have DMO in both eyes, injections need to be given in both eyes to many patients.
Given the above facts there appeared a clear need to develop new treatments for people with DMO. ARA 290 is a drug that has marked anti-inflammatory properties and has an effect in preventing the death of cells. As inflammation is known to play a role in the occurrence of DMO, it was thought that ARA 290 could potentially be helpful in treating patients with this condition. In light of this, the Investigators carried out this study to find out if ARA 290 was effective in drying the fluid in DMO. If this treatment was successful, benefits may have included a reduction of the demands on health care services and patient benefits of: self administration of the drug at home by the patients; a reduction in hospital visits; treatment of both eyes at once, reduced risks associated with injections; a more pleasant treatment (subcutaneous injection versus an injection into the eye).]]></description>
<content:encoded><![CDATA[<p>ARA 290-DMO is a prospective, open label, interventional, single centre, investigator led, phase II trial to examine the effect of ARA 290 on diabetic macular oedema in patients with type 1 or 2 diabetes.</p>
<p>The aim or primary objective of the study was to determine whether ARA 290 administered at a daily dose of 4mg subcutaneously for 12 weeks to patients with diabetes mellitus (DM) and DMO would have a beneficial effect on mean change in best corrected visual acuity (BCVA) from baseline values to week 12.</p>
]]></content:encoded>
<wfw:commentRss>https://sumiagro.org/product/cibinetide-ara-290-ra10/feed/</wfw:commentRss>
<slash:comments>0</slash:comments>
</item>
<item>
<title>SURVODUTIDE SUR5 ( SUR5,SUR10)</title>
<link>https://sumiagro.org/product/survodutide-sur5-sur5sur10/</link>
<comments>https://sumiagro.org/product/survodutide-sur5-sur5sur10/#respond</comments>
<dc:creator><![CDATA[Administrator]]></dc:creator>
<pubDate>Fri, 13 Feb 2026 03:52:36 +0000</pubDate>
<guid isPermaLink="false">https://sumiagro.org/?post_type=product&p=29476</guid>
<description><![CDATA[<div class="padded nooverflow">Chemical. CAS: 2805997-46-8. Formula: C192H289N47O61. MW: 4231.7. Soluble in water (10mg/ml). Survodutide is a novel long-acting dual glucagon-like peptide-1 (GLP-1) receptor and glucagon receptor (GCGR) agonist. Survodutide potently activates the GLP-1R signaling pathway to stimulate glucose-dependent insulin secretion through activity at the GCG receptor (GCGR) or the GLP-1R. Survodutide is a synthetic peptide glucagon analog rather than an analog of oxyntomodulin, unlike other dual GLP-1/glucagon dual agonists. Survodutide binds human and mouse GCGR and GLP-1R and stimulates insulin secretion in isolated mouse, rat and perifused human pancreatic islets. Survodutide is used in studies of obesity and type 2 diabetes (T2D) and is designed enhancing energy expenditure and fat metabolism and decreasing food intake. Survodutide comprises a 29 amino acid linear synthetic peptide conjugated to a C18 fatty diacid moiety through a hydrophilic linker at the lysine residue at position 24. Due to this moiety, the compound is highly bound to albumin in the plasma which prolongs its half-life. It contains one non-coded amino acid residue (Ac4c, 1-Aminocyclobutane-1-carboxylic acid) at position 2, well established as the site of proteolytic activity for dipeptidyl peptidase-4.</div>
<div class="separator"></div>
<div class="column-20 floatleft">
<div class="padded"><strong>Molecular Formula:</strong></div>
</div>
<div class="padded nooverflow">C192H289N47O61</div>
<div class="separator"></div>
<div class="column-20 floatleft">
<div class="padded"><strong>Molecular Weight:</strong></div>
</div>
<div class="padded nooverflow">4231.7</div>
<div class="separator"></div>
<div class="column-20 floatleft">
<div class="padded"><strong>Package Type:</strong></div>
</div>
<div class="padded nooverflow">Vial</div>
<div class="separator"></div>
<div class="column-20 floatleft">
<div class="padded"><strong>Product Description:</strong></div>
</div>
<div class="padded nooverflow">Survodutide is a novel long-acting dual glucagon-like peptide-1 (GLP-1) receptor and glucagon receptor (GCGR) agonist. Survodutide potently activates the GLP-1R signaling pathway to stimulate glucose-dependent insulin secretion through activity at the GCG receptor (GCGR) or the GLP-1R. Survodutide is a synthetic peptide glucagon analog rather than an analog of oxyntomodulin, unlike other dual GLP-1/glucagon dual agonists. Survodutide binds human and mouse GCGR and GLP-1R and stimulates insulin secretion in isolated mouse, rat and perifused human pancreatic islets. Survodutide is used in studies of obesity and type 2 diabetes (T2D) and is designed enhancing energy expenditure and fat metabolism and decreasing food intake. Survodutide comprises a 29 amino acid linear synthetic peptide conjugated to a C18 fatty diacid moiety through a hydrophilic linker at the lysine residue at position 24. Due to this moiety, the compound is highly bound to albumin in the plasma which prolongs its half-life. It contains one non-coded amino acid residue (Ac4c, 1-Aminocyclobutane-1-carboxylic acid) at position 2, well established as the site of proteolytic activity for dipeptidyl peptidase-4.</div>
<div class="separator"></div>
<div class="column-20 floatleft">
<div class="padded"><strong>Purity:</strong></div>
</div>
<div class="padded nooverflow">>98% (HPLC)</div>
<div class="separator"></div>
<div class="column-20 floatleft">
<div class="padded"><strong>Sequence:</strong></div>
</div>
<div class="padded nooverflow">H-His-{Ac4c}-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Glu-Arg-Ala-Ala-Lys-Asp-Phe-Ile-{diacid-C18-gamma-Glu-Gly-Ser-Gly-Ser-Gly-Gly-Lys}-Trp-Leu-Glu-Ser-Ala-NH2</div>]]></description>
<content:encoded><![CDATA[<p>Survodutide (BI-456906) is a glucagon and glucagon-like peptide 1 (GLP-1) receptor (GLP Receptor) agonist.<br />
BI 456906 is a once-weekly, injectable GCGR/GLP-1R dual agonist currently in Phase II clinical development for obesity, type 2 diabetes, and NASH. This research describe biomarkers that were applied in the discovery of BI 456906 as a balanced dual agonist and demonstrate that engagement of both the GCGR and GLP-1R achieves a bodyweight-lowering efficacy exceeding that of a selective GLP-1R agonist. Applying mRNA sequencing, researchers provide novel insights into potential mechanisms of action of BI 456906 in hepatocytes, offering a scientific rationale that is supportive of the clinical development for BI 456906 in people with NASH. [1]
Survodutide (BI 456906) is a unimolecular dual agonist of the glucagon and GLP-1 receptors. In addition to anorexigenic effects of GLP-1 receptor stimulation, glucagon receptor agonism may directly elicit hepatic fat loss by increasing energy expenditure, decrease hepatic inflammation by improving mitochondrial function, and impact hepatic fibrosis by reducing stellate cell activation.</p>
]]></content:encoded>
<wfw:commentRss>https://sumiagro.org/product/survodutide-sur5-sur5sur10/feed/</wfw:commentRss>
<slash:comments>0</slash:comments>
</item>
<item>
<title>SEMAGLUTIDE SM5 (SM5 SM10 SM15 SM20 SM30)</title>
<link>https://sumiagro.org/product/semaglutide-sm5-sm5-sm10-sm15-sm20-sm30/</link>
<comments>https://sumiagro.org/product/semaglutide-sm5-sm5-sm10-sm15-sm20-sm30/#respond</comments>
<dc:creator><![CDATA[Administrator]]></dc:creator>
<pubDate>Fri, 13 Feb 2026 03:36:52 +0000</pubDate>
<guid isPermaLink="false">https://sumiagro.org/?post_type=product&p=29468</guid>
<description><![CDATA[<strong>Semaglutide (<a href="https://www.drugs.com/ozempic.html">Ozempic</a>, <a href="https://www.drugs.com/wegovy.html">Wegovy</a>, <a href="https://www.drugs.com/rybelsus.html">Rybelsus</a>) is a prescription <a href="https://www.drugs.com/drug-class/glp-1-receptor-agonists.html">GLP-1 medication</a> used for <a href="https://www.drugs.com/condition/obesity.html">weight loss</a> and weight management, <a href="https://www.drugs.com/condition/diabetes-mellitus-type-ii.html">type 2 diabetes</a> treatment, or to reduce the risk of <a href="https://www.drugs.com/condition/chronic-kidney-disease.html">chronic kidney disease</a> and major cardiovascular events in certain patients with type 2 diabetes. </strong>Semaglutide (Wegovy) is also used to treat metabolic dysfunction-associated <a href="https://www.drugs.com/condition/nonalcoholic-fatty-liver.html">steatohepatitis</a> (MASH), without cirrhosis of the liver.
Semaglutide injections are self-administered once weekly as an injection under the skin, and semaglutide pills are taken once daily.
Semaglutide works by reducing appetite, delaying gastric emptying, increasing insulin release, and lowering the amount of glucagon released. Semaglutide is a GLP-1 receptor agonist that mimics the behavior of the GLP-1 hormone, which is naturally released after eating.
Semaglutide brand names are Ozempic, Rybelsus, and Wegovy, all made by Novo Nordisk. There is no generic semaglutide available. Semaglutide FDA approval was first granted on December 5, 2017, for the brand Ozempic.]]></description>
<content:encoded><![CDATA[<p><strong>Semaglutide (<a href="https://www.drugs.com/ozempic.html">Ozempic</a>, <a href="https://www.drugs.com/wegovy.html">Wegovy</a>, <a href="https://www.drugs.com/rybelsus.html">Rybelsus</a>) is a prescription <a href="https://www.drugs.com/drug-class/glp-1-receptor-agonists.html">GLP-1 medication</a> used for <a href="https://www.drugs.com/condition/obesity.html">weight loss</a> and weight management, <a href="https://www.drugs.com/condition/diabetes-mellitus-type-ii.html">type 2 diabetes</a> treatment, or to reduce the risk of <a href="https://www.drugs.com/condition/chronic-kidney-disease.html">chronic kidney disease</a> and major cardiovascular events in certain patients with type 2 diabetes. </strong>Semaglutide (Wegovy) is also used to treat metabolic dysfunction-associated <a href="https://www.drugs.com/condition/nonalcoholic-fatty-liver.html">steatohepatitis</a> (MASH), without cirrhosis of the liver.</p>
]]></content:encoded>
<wfw:commentRss>https://sumiagro.org/product/semaglutide-sm5-sm5-sm10-sm15-sm20-sm30/feed/</wfw:commentRss>
<slash:comments>0</slash:comments>
</item>
<item>
<title>TIRZEPATIDE (TR5 TR10 TR15 TR20 TR30 TR40 TR50 TR60 TR70 TR80 TR90 TR100 TR110 TR120)</title>
<link>https://sumiagro.org/product/tirzepatide-tr5-tr10-tr15-tr20-tr30-tr40-tr50-tr60-tr70-tr80-tr90-tr100-tr110-tr120/</link>
<comments>https://sumiagro.org/product/tirzepatide-tr5-tr10-tr15-tr20-tr30-tr40-tr50-tr60-tr70-tr80-tr90-tr100-tr110-tr120/#respond</comments>
<dc:creator><![CDATA[Administrator]]></dc:creator>
<pubDate>Thu, 12 Feb 2026 16:16:54 +0000</pubDate>
<guid isPermaLink="false">https://sumiagro.org/?post_type=product&p=29456</guid>
<description><![CDATA[Tirzepatide injection is used to treat type 2 diabetes. It is used together with diet and exercise to help control your blood sugar. Tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist.
Tirzepatide injection is also used to help lose weight and keep the weight off in patients with obesity caused by certain conditions. It is also used to treat moderate to severe obstructive sleep apnea (OSA) in patients with obesity.]]></description>
<content:encoded><![CDATA[<p> </p>
<p>Tirzepatide is a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist used to improve glycemic control in Type 2 diabetes and for chronic weight management. It is a 39-amino acid synthetic peptide that is often supplied in 20 mg strengths (typically 20 mg/0.5 mL or similar concentrations in compounding scenarios) for once-weekly subcutaneous injection.</p>
]]></content:encoded>
<wfw:commentRss>https://sumiagro.org/product/tirzepatide-tr5-tr10-tr15-tr20-tr30-tr40-tr50-tr60-tr70-tr80-tr90-tr100-tr110-tr120/feed/</wfw:commentRss>
<slash:comments>0</slash:comments>
</item>
</channel>
</rss>